Radioligand imaging & treatment of prostate cancer
|
|
- Rosamond Parks
- 5 years ago
- Views:
Transcription
1 Radioligand imaging & treatment of prostate cancer Christiaan Schiepers, MD, PhD University of California Los Angeles
2 CANM-CAMRT JOINT ANNUAL CONFERENCE MARCH 22-24, 2018 VANCOUVER, B.C. I do not have a financial interest, arrangement or affiliation including receipt of honoraria or expenses with a commercial organization that may have a direct interest in the subject matter of my presentation.
3 PROSTATE CANCER AFTER PRIMARY SURGERY Within 10 years up to one third of patients manifest recurrent disease OVERALL Biochemical recurrence free-survival Time since radical prostatectomy in years Walz J et al. BJU Int 2011 Thompson et al. AUA/ASTRO Guideline. J Urol. 2013
4 PROSTATE CANCER AFTER PRIMARY SURGERY 10 year risk of biochemical recurrence: 5% to 85% Dependent upon initial clinical and pathological characteristics Biochemical recurrence free-survival HIGH RISK ct3 = extra-prostatic extension Time since Radical Prostatectomy in years Walz J et al. BJU Int 2011
5 PSA level and Test Positivity. Radio-tracer Serum PSA 99m Tc-MDP > 7-10 ng/ml 18 F-FDG > 5 11 C- or 18 F-Choline > C-Acetate > C-Choline > 1-2 ng/ml/year PSA velocity 18 F-Fluciclovine >??? 68 Ga-PSMA-11 >???
6 Glutamate carboxy-peptidase 2 GCP-2 FOLH-1 PSMA
7
8 PSMA receptor Significantly over-expressed on prostate cancer cells Some primary prostate cancers do not express PSMA fold 5-10% negative scans Expression is even more increased in mcrpc
9 Radio-ligands PSMA-11 can be labeled with 68 Ga Diagnosis PSMA-617 can be labeled with 177 Lu Therapy
10 Prostate Specific Membrane Antigen Type II transmembrane glyco-protein PSMA function in prostate cells is still unknown
11 PSMA RESEARCH DATES BACK TO 1970S Biology Imaging Therapy LNCaP 7E11 Function 11 C 177 Lu 18 F 68 Ga NYS/Buffalo 7E11 (ProstaScint) Johns Hopkins/Georgetown Weill Cornell Heidelberg DCFPyl J591 PSMA11 PSMA617 PSMA1007
12 RADIOLIGANDS TARGET PSMA FOR IMAGING AND THERAPY PSMA (glutamate carboxypeptidase 2) Degree of expression correlates with the pathological grade and recurrence Internalization upon ligand binding PSMA-11 PSMA-617 PSMA-I&T Other probes: MIP1095 DCFBC DCFPyl PSMA1007 J591 mab 7E11 mab...
13 PSMA receptor expression Diagnosis & Staging
14 Radionuclide Gallium-68
15 CURRENT STATUS OF PSMA PET/CT Not an FDA or EMA approved probe for PET imaging PSMA PET/CT is standard of care in Australia, Israel, Germany, other European countries Most of current literature on 68 Ga-PSMA-11 (Heidelberg Compound) EAU guideline 2017: BCR at PSA >1 ng/ml: PET/CT is recommended using choline or PSMA (LE 2b, GR A). Multiple trials under way to establish accuracy and impact on management (e.g. NCT , NCT , NCT )
16 PSMA PET ACCURATELY LOCALIZES BCR Detection rate correlates with PSA level Metaanalysis of 22 studies / >1000 patients Predicted detection rate (mean ± 95%CI) Detection rate is superior Metaanalysis of 53 studies / >1500 patients Detection rate (mean ± 95%CI) 48% at % at % at 1.0 ng/ml Perera et al. Eur Urol 2016 Chung et al. Am J Nucl Med Mol Imaging 2014
17 BIOCHEMICAL RECURRENCE - BCR 61 y/o patient, Gleason 7, s/p prostatectomy 2013 PSA rising to 0.5 ng/ml in 2017 (12 months doubling time) 68 Ga-PSMA-11 PET PET/CT cect salvage LND confirmed 3/12 positive LNs
18 PSMA PET INDUCES CHANGE IN MANAGEMENT A PROSPECTIVE UCLA TRIAL Scheduling PET/CT Report + DVD + 1 month TREATMENT + 3 to 6 months Pre-Scan Questionnaire Q1 Intended change Post-Scan Questionnaire Q2 Implemented change Late Follow-up Questionnaire Q3 or File review/contact INTENDED TREATMENT BEFORE PET/CT INTENDED TREATMENT AFTER PET/CT ACTUAL IMPLEMENTED TREATMENT Intended Implemented MANAGEMENT CHANGES 62 (61%) 54 (53%) Conversion to Focal Treatment / New Focal Treatment 40 (40%) 29 (29%) Conversion to systemic treatment 12 (12%) 13 (13%) Conversion to active surveillance 5 (5%) 7 (7%) Change in Systemic Treatment 5 (5%) 5 (5%) Calais et al. J Nucl Med 2018 Mar;59(3):
19 PRIMARY STAGING 77 y/o patient, ipsa 7.1, GS 4+5=9, bone scan negative primary PCa, nodal metastases, bone metastases 68 Ga-PSMA-11 PET
20 p<0.001 p=0.002 PSMA PET DETECTS NODAL METASTASES AT PRIMARY STAGING 130 intermediate/high risk primary PCa 35 PET/CT, 95 PET/MR using 68 Ga-PSMA-11 standardized PLND with separated field histopathology Sens (%) Spec (%) PPV (%) NPV (%) Acc. (%) CT/MRI PSMA-PET Patientbased Fieldbased* Sens (%) Spec (%) PPV (%) NPV (%) Acc. (%) CT/MRI PSMA-PET Maurer,..., Eiber et al. J Urol 2015
21 INTEROBSERVER AGREEMENT IS SUBSTANTIAL 50 patient cases, 16 international readers Histopathology/imaging follow-up as reference standard * * * * * * * * T N Mb Mc *Fulfill predefined criteria: high or intermediate experience readers Fendler et al. J Nucl Med 2017
22 MI TNM CLASSIFICATION PROMISE Final diagnosis: mi T0 N0 M1a (PR, SD) b (oligo) Prostate Cancer Molecular Imaging Standard Evaluation Eiber, Fendler et al. J Nucl Med 2018 Mar;59(3):
23 18 F-AXUMIN VERSUS 68 GA-PSMA Head-to-head comparison of 68 Ga-PSMA-11 PET/CT and 18 F-Fluciclovine PET/CT in a case series of 10 patients with prostate cancer recurrence. J Calais et al. J Nucl Med Dec 14.
24 PSMA receptor expression Mapping for Radiation-Therapy
25 68 GA-PSMA PET/CT MAPPING OF EARLY BIOCHEMICAL RECURRENCE AFTER PRIMARY SURGERY IN 270 PATIENTS: IMPACT ON SALVAGE RADIOTHERAPY PLANNING J Calais - J Czernin M Eiber - WP Fendler - K Herrmann M Cao - N Nickols University of California Los Angeles Technical University of Munich Ludwig-Maximilians-University of Munich University of Essen J Nucl Med Feb;59(2): doi: /jnumed Epub 2017 Nov 9.
26 SALVAGE RADIATION THERAPY AUA / ASTRO GUIDELINE Rising PSA after radical prostatectomy without evidence for distant failure = Indication for salvage RT with / without ADT = Currently the only curative option Success depends upon: Absence of distant metastases Pre-RT PSA level the earlier the better: at 0.5 ng/ml, some say 0.1 ng/ml) Longer interval to biochemical recurrence predicts better response Gleason Score Tumor margins (positive predicts higher local recurrent disease) T,N stage (by pathology and by conventional imaging) Re-staging evaluation in a patient with PSA recurrence may be considered. (Option; Evidence Strength: Grade C) Stephenson et al. JAMA Stephenson at al. J Clin Oncol Thompson et al. AUA/ASTRO Guideline. J Urol. 2013
27 SALVAGE RADIATION THERAPY Clinical Practice SRT is commonly initiated in patients with PSA level < 1 ng/ml when conventional imaging is not sensitive for detecting recurrence. SRT target volumes are usually drawn in the absence of radiographic evidence of recurrent disease.
28 SALVAGE RADIATION THERAPY Current Guidelines : RTOG EORTC Canada Australia TV = Target Volume Michalski et al. RTOG guidelines IJROBP 2010
29 RADIATION-THERAPY TARGET VOLUMES CONTOURING GTV CTV PTV DOSIMETRY SIMULATION Limited by healthy tissues (OAR)
30 SALVAGE RT : RESULTS > 80% of patients show PSA decrease after SRT ~ 67% have undetectable PSA levels ~ 50% free from biochemical, clinical, or radiographic progression (20%-80% depending on existing clinical-pathologic features) CAVE : For high-risk patients, 5-year biochemical failure rate after SRT reaches 70% Approximately 15% of these patients die within 10 years Moghanaki et al. Cancer 2012 Zumsteg et al. J Clin Oncol. 2016
31 SALVAGE RT : RESULTS In field recurrence after salvage RT in CTV is low: 14% (1) Recurrence outside the CTV is common: 86% (1) First recurrence: Prostate bed: 4% (1); 5% (2) Lymph Nodes: 89% (1); 27% (2) Bone: 6% (1); 64% (2) (1) with 11 C-Choline PET-CT (2) with conventional imaging 11 C-Choline PET-CT recurrences (red = histologically confirmed) (1) Parker et al. IJROBP (2) Jackson et al. BJU 2017
32 Eiber et al. JNM 2015 PET/CT USING PSMA Powerful tool to detect recurrence at an early stage (PSA<1) Displays new patterns of early recurrence (PSA<1) that we could not see before Detection rates ~50% for PSA < 0.5 ng/ml 68 Ga-PSMA PET/CT has thus the potential to guide and improve target volume delineations for SRT.
33 PATIENT POPULATION SRT CANDIDATES PSMA PET/CT Radical prostatectomy Biochemical recurrence No prior radiation therapy PSA < 1 ng/ml Databases from : Technical University of Munich (TUM; n=147) University of California Los Angeles (UCLA, n=47) Ludwig-Maximilians-University of Munich (LMU; n=40) University of Essen (n=36) Total N = 270
34 PRIMARY OBJECTIVES Where are the PSMA positive lesions located? In-field or Out-of-field? How often outside radiation treatment field? Do the contours cover the recurrences? Potential impact of PSMA PET/CT on SRT planning?
35 METHODS 1 consensus CTV on CT PSMA PET/CT Blinded by radiation oncologist Orange = Prostate CTV Green = Pelvic LN CTV
36 METHODS
37 METHODS
38 PATIENT CHARACTERISTICS Characteristics n = 270 Age at PET/CT, median (years) 67 ± 8 (range 43-90) Initial PSA before Surgery, median (ng/ml) 8.3 ± 22.2 (range ) < (48%) 10 < (17%) (14%) Unknown 56 (21%) Gleason Score 6 33 (12%) (50%) 8 86 (32%) Unknown 16 (6%) Pathologic Primary Tumor Staging (pt) pt2 98 (36%) pt3 142 (52.5%) pt4 2 (0.7%) Unknown 27 (10%) Pathologic Regional LN Staging (pn) pn0 166 (61.5%) pn1 54 (20%) pnx 50 (18.5%) Positive Margin R0 152 (56.5%) R1 67 (25%) Unknown 51 (19%) NCCN Risk Group Low 4 (1.5%) Intermediate 36 (13.5%) High 163 (60.5%) N1 54 (20%) Unknown 13 (5%) ADT within 6 months prior to imaging 33 (12.5%) Time between surgery and PET/CT, median (months) 25 ± 45 (range 2-272) PSA value prior to PET/CT, median (ng/ml) 0.48 ± 0.25 (range )
39 PSMA PET/CT FINDINGS
40 PSMA PET/CT FINDINGS
41 INSIDE THE CTV
42 DISTAL EXTERNAL ILIAC RECURRENCE
43 EXTRA-PELVIC RECURRENCE
44 3D MAPPING OF RECURRENCES
45 3D MAPPING OF RECURRENCES 132/270 (49%) positive 68 Ga-PSMA PET/CT 52/270 (19%) at least one PSMA avid lesion not covered by consensus CTVs. 33/270 (12%) extra-pelvic metastases bone (23/270, 9%) 19/270 (7%) PSMA avid pelvic lesion(s) not covered by consensus CTVs without extrapelvic metastases perirectal LNs (16/270, 6%) distal external iliac LNs (9/270, 3%)
46 PSA LEVELS AND PSMA POSITIVITY 153 patients PSA < 0.5 (very low PSA group) 117 patients PSA > (low PSA group) PSA < < 0.5 N PSMA % 62 41% 70 60% p = Outside of CTV 52 19% 20 13% 29 25% p = 0.4
47 TAKE HOME MESSAGES 68 GA-PSMA PET/CT MAPPING OF EARLY BIOCHEMICAL RECURRENCE AFTER PRIMARY SURGERY IN 270 PATIENTS: IMPACT ON SALVAGE RADIOTHERAPY PLANNING 68 Ga-PSMA PET/CT detected lesions outside the consensus target volumes in 20% of patients with early failure (PSA < 1) after surgery thus suggesting a major impact on SRT planning Most frequent lesions outside the CTV are in: bone, perirectal, distal external iliac nodes 68 Ga-PSMA PET/CT detected lesions inside the consensus target volumes in 30% of patients, suggesting a minor impact on SRT planning (dose boost) Overall, 68 Ga-PSMA PET/CT may impact SRT in half of patients with PSA < 1
48 PSMA receptor expression Radioligand Imaging and Therapy
49 Prostate Specific Membrane Antigen There are multiple PSMA ligands available PSMA-11 can be labeled with 68 Ga Diagnosis PSMA-617 can be labeled with 177 Lu Therapy
50 CLINICAL TRIALS AT UCLA PET/CT imaging BCR Primary Any 68 Ga-PSMA PET/CT for detection of recurrent prostate cancer after initial therapy (ongoing) 68 Ga PSMA PET/CT before prostatectomy in patients with newly diagnosed prostate cancer (ongoing) Change in management after 68 Ga PSMA PET/CT (initiation Q1 2018)
51 Radionuclide Lutetium-177
52 Rahbar et al. J Nucl Med 2017; Fendler et al. Oncotarget 2017 PSMA RADIOLIGAND THERAPY Reduces Serum PSA Levels Reduces Tumor Size Improves Pain and QoL
53 CLINICAL TRIALS AT UCLA mcrpc Radioligand Therapy PSMA-directed endoradiotherapy of castration-resistant Prostate Cancer (RESIST-PC). A phase II clinical trial. (started Q4 2017)
54 PATIENT #2 Age 71 yrs Diagnosis April 2016 Gleason PSA 2000 ng/ml Multiple bone metastases ADT + Chemo 2016 PSA 8.5 ng/ml August 2016 ADT 2 nd G Bone scan PET/CT PSA 7-JUN OCT ng/ml
55 PATIENT #2 PET/CT 23-OCT-2017
56 PATIENT #2 PLANAR + SPECT/CT TREATMENT WITH 6 GBQ LU-177 ON 13-NOV Lu-PSMA h 177 Lu-PSMA h 177 Lu-PSMA h 177 Lu-PSMA h 68 Ga-PSMA OCT-2017
57 PATIENT #2 TREATMENT WITH 6 GBQ LU-177 ON 13-NOV OCT-2017 Before Treatment 10-JAN-2018 After Treatment
58 SUMMARY 68 GA-PSMA IMAGING PSMA PET/CT provides superior tumor detection at biochemical recurrence (50% at PSA 0.5 ng/ml) leading to change in management in about 50% of patients PSMA PET/CT provides high accuracy for primary nodal staging of intermediate/high risk disease (75% SE, 99% SP); PET can be combined to improve mpmri Interobserver agreement is substantial after 1 hour reader training PROMISE criteria propose standardized reporting Outlook: Several ongoing trials aim at approval of imaging probes (DCFPyl, PSMA11 and MIP1095)
59 SUMMARY 177 LU-PSMA THERAPY Phase II trial started and ongoing at UCLA for mcrpc after failure of other treatments Approval for 100 patients under IND 28 patients enrolled, 2 had progressive disease after 1 cycle. Nobody has yet finished the trial of 4 cycles (1 per 8 weeks) No significant PSA change during the first 2 cycles One third of patients report subjective response
Prostate Cancer Local or distant recurrence?
Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationMolecular Imaging in Prostate Cancer. Carlos Artigas Nuclear Medicine Institut Jules Bordet
Molecular Imaging in Prostate Cancer Carlos Artigas Nuclear Medicine Institut Jules Bordet Introduction 3 different stages of the disease Local treatment with curative intent Introduction 3 different stages
More informationNuclear Medicine related studies for Prostate cancer
Nuclear Medicine related studies for Prostate cancer ผศ. พญ. ว ชชนา จาร ญร ตน Wichana Chamroonrat, MD 14 กรกฎาคม 2560 เวลา 15:15-15:40น. ณ ห องประช มท านผ หญ ง ช น 5 อาคารศ นย การแพทย ส ร ก ต Courtesy
More informationPET/CT imaging and RIT of prostate cancer. Kirsten Bouchelouche, MD, DMSc PET & Cyclotron Unit Rigshospitalet, Copenhagen Denmark
PET/CT imaging and RIT of prostate cancer Kirsten Bouchelouche, MD, DMSc PET & Cyclotron Unit Rigshospitalet, Copenhagen Denmark Prostate cancer Prostate cancer is the most common malignancy in men Imaging
More informationGa 68 -HBED- PSMA. A/ProfLouise Emmett St Vincent s Hospital Sydney
Ga 68 -HBED- PSMA A/ProfLouise Emmett St Vincent s Hospital Sydney Glu-NH-CO-NH-Lys-(Ahx)- [68Ga(HBED-CC)] Prostate specific membrane antigen 35 pub-med publications 15 clinical 3 retrospective larger
More informationPSMA PET in patients with prostate cancer
PSMA PET in patients with prostate cancer Thomas Hope, MD Assistant Professor of Radiology, UCSF Abdominal Imaging and Nuclear Medicine Co-director, PET/MRI Chief of MRI, San Francisco VA Medical Center
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationστη σταδιοποίηση του καρκίνου του προστάτη Γ. Αρσος, Γ Εργ. Πυρηνικής Ιατρικής ΑΠΘ, ΓΝΘ Παπαγεωργίου
Η θέση του PET/CT στη σταδιοποίηση του καρκίνου του προστάτη Γ. Αρσος, Γ Εργ. Πυρηνικής Ιατρικής ΑΠΘ, ΓΝΘ Παπαγεωργίου 2014 : the Guidelines year. PRINCIPLES OF IMAGING Imaging is performed for the detection
More informationPSMA PET SCANNING AND THERANOSTICS IN PROSTATE CANCER KEVIN TRACEY, MD, FRCPC PRECISION DIAGNSOTIC IMAGING REGIONAL PET/CT CENTRE
PSMA PET SCANNING AND THERANOSTICS IN PROSTATE CANCER KEVIN TRACEY, MD, FRCPC PRECISION DIAGNSOTIC IMAGING REGIONAL PET/CT CENTRE DISCLOSURES/CONFLICTS NONE OBJECTIVES Understand current diagnostic role
More informationNovel Imaging in Advanced Prostate Cancer
Novel Imaging in Advanced Prostate Cancer Robert J. Hamilton, MD MPH FRCSC Princess Margaret Cancer Centre ICUC Saturday January 21, 2017 Company/Organizati Details Faculty/Presenter on Disclosures I am
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More information10/30/2018. Martha K. Terris, MD Witherington Distinguished Professor and Chair Medical College of Georgia Urology November 5, 2018
Martha K. Terris, MD Witherington Distinguished Professor and Chair Medical College of Georgia Urology November 5, 2018 Elevated PSA and/or nodule on digital rectal examination Prostate biopsies If initial
More informationManaging Prostate Cancer After Initital Treatment Fails: Are There Good Next Steps?
Managing Prostate Cancer After Initital Treatment Fails: Are There Good Next Steps? Michael J Zelefsky, M.D. Professor of Radiation Oncology Chief Brachytherapy Service Department of Radiation Oncology
More informationFLUCICLOVINE: 1 ST FDA APPROVED F-18 PET IMAGING AGENT FOR RECURRENT PROSTATE CANCER
FLUCICLOVINE: 1 ST FDA APPROVED F-18 PET IMAGING AGENT FOR RECURRENT PROSTATE CANCER KEVIN P BANKS, MD SAN ANTONIO MILITARY MEDICAL CENTER ASSISTANT PROFESSOR OF RADIOLOGY, USU I HAVE NO FINANCIAL DISCLOSURES.
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationUsing PET/CT in Prostate Cancer
Using PET/CT in Prostate Cancer Legal Disclaimer These materials were prepared in good faith by MITA as a service to the profession and are believed to be reliable based on current scientific literature.
More informationINDICATIONS AND USAGE
1. INDICATIONS AND USAGE a) Axumin is indicated for positron emission tomography (PET) in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following
More informationLong-term Results of a Comparative PET/CT and PET/MRI Study of 11 C-Acetate and 18 F-Fluorocholine for Restaging of Early Recurrent Prostate Cancer
ORIGINAL ARTICLE Long-term Results of a Comparative PET/CT and PET/MRI Study of 11 C-Acetate and 18 F-Fluorocholine for Restaging of Early Recurrent Prostate Cancer Giorgio Lamanna, MD,* Claire Tabouret-Viaud,
More informationRadical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease
Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after
More informationSIMPOSIO. Radioterapia stereotassica e nuovi farmaci nel tumore e della prostata metastatico
SIMPOSIO Radioterapia stereotassica e nuovi farmaci nel tumore e della prostata metastatico Definition of Oligometastatic PCa 1-3 synchronous metastases (bone and/or lymph nodes) 2-5 synchronous metastases
More informationAlberto Briganti, M.D., PhD
Alberto Briganti, M.D., PhD Professore Orinario di Urologia IRCCS San Raffaele Divisione di Oncologia / Unità di Urologia Urological Research Institute (URI) Università Vita-Salute San Raffaele, Milano
More informationLow risk. Objectives. Case-based question 1. Evidence-based utilization of imaging in prostate cancer
Evidence-based utilization of imaging in prostate cancer Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Objectives State the modalities,
More informationDebate: Whole pelvic RT for high risk prostate cancer??
Debate: Whole pelvic RT for high risk prostate cancer?? WPRT well, at least it ll get the job done.or will it? Andrew K. Lee, MD, MPH Associate Professor Department of Radiation Oncology Using T-stage,
More informationUpdates in Prostate Cancer Treatment 2018
Updates in Prostate Cancer Treatment 2018 Mountain States Cancer Conference Elaine T. Lam, MD November 3, 2018 Learning Objectives Understand the difference between hormone sensitive and castration resistant
More informationPSMA Targeted radionuclide therapy in Prostate Cancer
PSMA Targeted radionuclide therapy in Prostate Cancer Tawatchai Chaiwatanarat Division of Nuclear Medicine Department of Radiology Chulalongkorn University Bangkok, Thailand * cell si ze ~20 µm Radionuclide
More informationWhole Body MRI. Dr. Nina Tunariu. Prostate Cancer recurrence, progression and restaging
Whole Body MRI Prostate Cancer recurrence, progression and restaging Dr. Nina Tunariu Consultant Radiology Drug Development Unit and Prostate Targeted Therapies Group 12-13 Janeiro 2018 Evolving Treatment
More informationPET in Prostate Cancer
PET in Prostate Cancer Tom R. Miller, M.D., Ph.D. Mallinckrodt Institute of Radiology Washington University School of Medicine St. Louis, Missouri, USA Prostate Imaging Bone Scintigraphy primarily for
More informationShort summary of published results of PET with fluoromethylcholine (18F) in prostate cancer
Short summary of published results of PET with fluoromethylcholine (18F) in prostate cancer JN TALBOT and all the team of Service de Médecine Nucléaire Hôpital Tenon et Université Pierre et Marie Curie,
More informationHigh Intensity Focused Ultrasounds for the treatment of Prostate Cancers Clinical update November D. Maruzzi - L. Ruggera
High Intensity Focused Ultrasounds for the treatment of Prostate Cancers Clinical update November 2014 D. Maruzzi - L. Ruggera HIFU development Second prototype 1995-2000 Integrated Imaging 2006-2010 1993
More informationAdjuvant and Salvage Radiation for Prostate Cancer. Savita Dandapani, MD, PhD
Adjuvant and Salvage Radiation for Prostate Cancer Savita Dandapani, MD, PhD DISCLOSURES I am a consultant for Reflexion, receive funding from Bayer, and on the Speaker s Bureau with Astra Zeneca. Post-prostatectomy
More informationDoes Imaging of Advanced PC change a suggested treatment?
Does Imaging of Advanced PC change a suggested treatment? Professor Bertrand Tombal, MD, PhD Cliniques universitaires Saint-Luc Université catholique de Louvain Brussels, Belgium Credentials and conflict
More informationPRECISION IMAGING: QUANTITATIVE, MOLECULAR AND IMAGE-GUIDED TECHNOLOGIES
PRECISION IMAGING: QUANTITATIVE, MOLECULAR AND IMAGE-GUIDED TECHNOLOGIES Day 3 Authors: Tade, Funmilayo; Akin-Akintayo Oladunni; Schuster, David M. Lab Training Module 1: Introduction to the basics of
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationLutetium-177 PSMA (LuPSMA) Theranostic Phase II trial: Efficacy, safety and QoL in patients
Lutetium-177 PSMA (LuPSMA) Theranostic Phase II trial: Efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA M. S. Hofman, S. Sandhu, P. Eu, P. Jackson, T. Akhurst,
More informationControversies in Prostate Cancer Screening
Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations
More informationProstate Cancer in comparison to Radiotherapy alone:
Prostate Cancer in comparison to Radiotherapy alone: 1 RTOG 86-10 (2001) 456 patients with > a-goserelin 2 month before RTand during RT + Cyproterone acetate (1 month) vs b-pelvic irradiation (50 gy) +
More informationPhillip J. Koo, MD Division Chief of Diagnostic Imaging Banner MD Anderson Cancer Center, USA
ADVANCED PET IMAGING IN PROSTATE CANCER Phillip J. Koo, MD Division Chief of Diagnostic Imaging Banner MD Anderson Cancer Center, USA PET, positron-emission tomography DISCLAIMER Please note: The views
More informationWhen radical prostatectomy is not enough: The evolving role of postoperative
When radical prostatectomy is not enough: The evolving role of postoperative radiation therapy Dr Tom Pickles Clinical Associate Professor, UBC. Chair, Provincial Genito-Urinary Tumour Group BC Cancer
More informationLinac Based SBRT for Low-intermediate Risk Prostate Cancer in 5 Fractions: Preliminary Report of a Phase II Study with FFF Delivery
Linac Based SBRT for Low-intermediate Risk Prostate Cancer in 5 Fractions: Preliminary Report of a Phase II Study with FFF Delivery FILIPPO ALONGI MD Radiation Oncology & Radiosurgery Istituto Clinico
More informationPET imaging of cancer metabolism is commonly performed with F18
PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism
More information2018 ASTRO Refresher Course: Prostate Cancer. Timur Mitin, MD PhD Oregon Health and Science University
2018 ASTRO Refresher Course: Prostate Cancer Timur Mitin, MD PhD Oregon Health and Science University Disclosures UpToDate Chapter author, royalties Oregon Health and Science University Practicing Radiation
More informationImage-guided radiotherapy (IGRT) in oligometastatic recurrent prostate cancer
Image-guided radiotherapy (IGRT) in oligometastatic recurrent prostate cancer Piet Dirix MD, PhD Radiation Oncology Iridium Cancer Network www.iridiumkankernetwerk.be Partner Leuvens Kankerinstituut UZ
More informationThe Role of Adjuvant vs Salvage Radiation Therapy after Prostatectomy. Dr. Matt Andrews Supervisor: Dr. David Bowes
The Role of Adjuvant vs Salvage Radiation Therapy after Prostatectomy Dr. Matt Andrews Supervisor: Dr. David Bowes Objectives Discuss the evidence for adjuvant radiotherapy (ART) EORTC, SWOG, ARO Current
More informationL approccio alle stazioni linfonodali in presentazione di malattia ed all eventuale recidiva nodale: il punto di vista dell urologo
L approccio alle stazioni linfonodali in presentazione di malattia ed all eventuale recidiva nodale: il punto di vista dell urologo Paolo Gontero Division of Urology Città della Salute e della Scienza
More informationProviding Treatment Information for Prostate Cancer Patients
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
More informationPSA is rising: What to do? After curative intended radiotherapy: More local options?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung
More informationClinical Case Conference
Clinical Case Conference Intermediate-risk prostate cancer 08/06/2014 Long Pham Clinical Case 64 yo man was found to have elevated PSA of 8.65. TRUS-biopies were negative. Surveillance PSA was 7.2 in 3
More informationPROSTATE CANCER SURVEILLANCE
PROSTATE CANCER SURVEILLANCE ESMO Preceptorship on Prostate Cancer Singapore, 15-16 November 2017 Rosa Nadal National Cancer Institute, NIH Bethesda, USA DISCLOSURE No conflicts of interest to declare
More informationMR-US Fusion Guided Biopsy: Is it fulfilling expectations?
MR-US Fusion Guided Biopsy: Is it fulfilling expectations? Kenneth L. Gage MD, PhD Assistant Member Department of Diagnostic Imaging and Interventional Radiology 4 th Annual New Frontiers in Urologic Oncology
More informationJ Reinfelder, M Beck, P Goebell, P Ritt, J Sanders, T Kuwert, B Wullich, D Schmidt
First Experience with SPECT/CT Using a 99mTc-Labeled Inhibitor for Prostate- Specific Membrane Antigen in Patients with Biochemical Recurrence of Prostate Cancer J Reinfelder, M Beck, P Goebell, P Ritt,
More informationProstate cancer (PC) is the most common non-cutaneous malignancy in adult males in
A Short Review of Prostate Cancer Molecular Imaging Jaspreet S. Batra, MD, and Simin Dadparvar, MD Background: Prostate cancer (PC) is the most common non-cutaneous malignancy in adult males in the United
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationPORT after RP. Adjuvant. Salvage
PORT after RP Adjuvant Or Salvage RT after RP 40-50% PSA relapse after RP in HR Definition: PSA should be undetectable within 6 weeks of RP Initial PSA is measured 6-12 weeks after RP AUA defines biochemical
More informationHybrid Imaging SPECT/CT PET/CT PET/MRI. SNMMI Southwest Chapter Aaron C. Jessop, MD
Hybrid Imaging SPECT/CT PET/CT PET/MRI SNMMI Southwest Chapter 2014 Aaron C. Jessop, MD Assistant Professor, Department of Nuclear Medicine UT MD Anderson Cancer Center, Houston, Texas Complimentary role
More informationModern Dose Fractionation and Treatment Techniques for Definitive Prostate RT
Modern Dose Fractionation and Treatment Techniques for Definitive Prostate RT Daniel J Bourgeois, III MD, MPH Board Certified Radiation Oncologist Southeast Louisiana Radiation Oncology Group (SLROG) Disclosures
More informationVALUE OF PSA AS TUMOUR MARKER OF RELAPSE AND RESPONSE. ELENA CASTRO Spanish National Cancer Research Centre
VALUE OF PSA AS TUMOUR MARKER OF RELAPSE AND RESPONSE ELENA CASTRO Spanish National Cancer Research Centre Prostate Preceptorship. Lugano 17-18 October 2017 Prostate Specific Antigen (PSA) has a role in:
More informationIrreversible Electroporation for the Treatment of Recurrent Prostate Cancer
Irreversible Electroporation for the Treatment of Recurrent Prostate Cancer after prostatectomy, radiation therapy and HiFU R. Schwartzberg, E. Günther, N. Klein, S. Zapf, R. El-Idrissi, J. Cooper, B.
More informationPaul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia
Paul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia Virginia - Chesapeake Bay Landfall: Virginia Beach, April 29 th, 1607 PSA Failure after Radical Prostatectomy
More informationConceptual basis for active surveillance
Conceptual basis for active surveillance 1. Screening results in overdiagnosis 2. Clinically insignificant disease can be identified 3. All treatments have significant side effects and cost. 4. Delayed
More informationRadioimmunoscintigraphy (Monoclonal Antibody Imaging) With Indium 111 Capromab Pendetide for Prostate Cancer
Last Review Status/Date: December 2016 Page: 1 of 9 Antibody Imaging) With Indium 111 Capromab Description Radioimmunoscintigraphy (RIS) involves the administration of radiolabeled monoclonal antibodies
More informationGUIDELINES ON PROSTATE CANCER
10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal
More informationOverview of Radiotherapy for Clinically Localized Prostate Cancer
Session 16A Invited lectures: Prostate - H&N. Overview of Radiotherapy for Clinically Localized Prostate Cancer Mack Roach III, MD Department of Radiation Oncology UCSF Helen Diller Family Comprehensive
More informationProstate MRI for local staging and surgical planning in prostate cancer
Prostate MRI for local staging and surgical planning in prostate cancer 15th Annual Floyd A. Fried Advances in Urology Symposium June 23, 2017 Ray Tan, MD, MSHPM Assistant Professor Disclosures None Objectives
More informationFinancial and Other Disclosures
Financial and Other Disclosures Off-label use of drugs, devices, or other agents: None Data from IRB-approved human research is not presented I have the following financial interests or relationships to
More informationColorectal Cancer and FDG PET/CT
Hybrid imaging in colorectal & esophageal cancer Emmanuel Deshayes IAEA WorkShop, November 2017 Colorectal Cancer and FDG PET/CT 1 Clinical background Cancer of the colon and rectum is one of the most
More informationNew Concepts in PET Imaging Prostate Cancer
New Concepts in PET Imaging Prostate Cancer Leonard G. Gomella, MD Chairman, Department of Urology Director Sidney Kimmel Cancer Network Sidney Kimmel Cancer Center Thomas Jefferson University Philadelphia,
More informationMRI and metastases of PCa
MRI and metastases of PCa François CORNUD Céline COUVIDAT David EISS Arnaud LEFEVRE IRM Paris 16, France, Paris, France Université Paris Descartes, Paris, France When imaging should be considered for detection
More informationGUIDELINEs ON PROSTATE CANCER
GUIDELINEs ON PROSTATE CANCER (Text update March 2005: an update is foreseen for publication in 2010. Readers are kindly advised to consult the 2009 full text print of the PCa guidelines for the most recent
More informationARRO-Case Postoperative Radiotherapy in Prostate Cancer
ARRO-Case Postoperative Radiotherapy in Prostate Cancer Kara Downs Romano, Daniel Trifiletti, Timothy Showalter Radiation Oncology University of Virginia Charlottesville, VA Case: HPI 64 year old man with
More information1 TRIAL OVERVIEW SAKK 08/15
PROMET 1 TRIAL OVERVIEW SAKK 08/15 Sponsor: Trial Title: Short Title / Trial ID: Protocol Version and Date: Swiss Group for Clinical Cancer Research (SAKK) PROMET - Multicenter, Randomized Phase II Trial
More informationStrategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer
Strategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer Daisaku Hirano, MD Department of Urology Higashi- matsuyama Municipal Hospital, Higashi- matsuyama- city, Saitama- prefecture,
More informationStaging of Prostatic Carcinoma - The evolving use of SPECT-CT and Positron Emission Tomography (PET)
Staging of Prostatic Carcinoma - The evolving use of SPECT-CT and Positron Emission Tomography (PET) Poster No.: C-2477 Congress: ECR 2015 Type: Educational Exhibit Authors: B. Rawal, N. Vasdev, R. P.
More informationIntroduction. Original Article
bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after
More informationUniversity of Groningen. Morphological aspects of recurrent prostate cancer Rybalov, Maxim
University of Groningen Morphological aspects of recurrent prostate cancer Rybalov, Maxim IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it.
More informationAssessment of Skeletal Metastases in Prostate Cancer: 68Ga-PSMA PET vs 99mTc-MDP WBBS - A Case Series
Assessment of Skeletal Metastases in Prostate Cancer: 68Ga-PSMA PET vs 99mTc-MDP WBBS - A Case Series Poster No.: R-0094 Congress: 2016 ASM Type: Scientific Exhibit Authors: O. Bennett, Y.-T. T. Huang;
More informationQuality Variation and Clinical Impact in Head and Neck IMRT
Quality Variation and Clinical Impact in Head and Neck IMRT 6 th IMRT Symposium, New York Sep. 20, 2010 K.S. Clifford Chao, MD Chairman, Combined Radiation Oncology, New York Presbyterian Hospital Chairman,
More informationCase Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationNCCN Guidelines for Prostate V Meeting on 06/28/18
Guideline Page and Request PROS-2 through PROS-11 and PROS-D (pages 3 and 4). External request from GenomeDx Biosciences Request the NCCN Prostate Cancer Guidelines Panel to review the data in support
More informationStrengthening the weakest link: improving tumour definition
Strengthening the weakest link: improving tumour definition Marianne C Aznar marianne.aznar@manchester.ac.uk University of Manchester / The Christie NHS Clinical Trial Service Unit, University of Oxford
More informationOligometastasis. Körperstereotaxie bei oligo-metastasiertem Prostatakarzinom wann und wie in Kombination mit Systemtherapie?
Körperstereotaxie bei oligo-metastasiertem Prostatakarzinom wann und wie in Kombination mit Systemtherapie? Daniel M. Aebersold 09. Dezember 2016 Oligometastasis JCO, 1995 1 Oligometastasis: Chance for
More informationSalvage HDR Brachytherapy. Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK
Salvage HDR Brachytherapy Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK Disclosures Still No financial disclosures! Limited personal experience of HDR Brachy as salvage option
More informationExternal Beam Radiation Therapy for Low/Intermediate Risk Prostate Cancer
External Beam Therapy for Low/Intermediate Risk Prostate Cancer Jeff Michalski, M.D. The Carlos A. Perez Distinguished Professor of Department of and Siteman Cancer Center Learning Objectives Understand
More informationPET/CT in Gynaecological Cancers. Stroobants Sigrid, MD, PhD Departement of Nuclear Medicine University Hospital,Antwerp
PET/CT in Gynaecological Cancers Stroobants Sigrid, MD, PhD Departement of Nuclear Medicine University Hospital,Antwerp Cervix cancer Outline of this talk Initial staging Treatment monitoring/guidance
More informationHigh Risk Localized Prostate Cancer Treatment Should Start with RT
High Risk Localized Prostate Cancer Treatment Should Start with RT Jason A. Efstathiou, M.D., D.Phil. Assistant Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School 10
More informationThe Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology
The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology (specifically, lung cancer) 2/10/18 Jeffrey Kittel, MD Radiation Oncology, Aurora St. Luke s Medical Center Outline The history
More informationTargeting and Treating Cancer
Targeting and Treating Cancer Mark R. Baker, Chief Executive Officer Jefferies Healthcare Conference June 2015 Disclosure Notice This presentation may contain projections and other forward-looking statements
More informationNew research in prostate brachytherapy
New research in prostate brachytherapy Dr Ann Henry Associate Professor in Clinical Oncology University of Leeds and Leeds Cancer Centre PIVOTAL boost opening 2017 To evaluate - The benefits of pelvic
More informationProstate Cancer: from Beginning to End
Prostate Cancer: from Beginning to End Matthew D. Katz, M.D. Assistant Professor Urologic Oncology Robotic and Laparoscopic Surgery University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer
More informationPET-MRI in malignant bone tumours. Lars Stegger Department of Nuclear Medicine University Hospital Münster, Germany
PET-MRI in malignant bone tumours Lars Stegger Department of Nuclear Medicine University Hospital Münster, Germany Content From PET to PET/MRI General considerations Bone metastases Primary bone tumours
More informationPSMA-617 License Transaction. October 2, 2017
PSMA-617 License Transaction October 2, 2017 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending,
More informationEvidence of choline PET CT scan for detecting early recurrence or metastatic prostatic cancer
Original article Evidence of choline PET CT scan for detecting early recurrence or metastatic prostatic cancer Sachin Yallappa, Isthiakul Rizvi Glasgow Royal infirmary, Birmingham Queen Elizabeth Hospital,
More informationFocal Therapy is a Fool s Paradise : The whole prostate must be treated!
Focal Therapy is a Fool s Paradise : The whole prostate must be treated! Ofer Yossepowitch, MD Head, Department of Urology Tel Aviv Sourasky Medical Center Preaching against focal therapy in a focal therapy
More informationInterpretation of 11C choline PET/CT for the diagnosis of local relapse in radically treated prostate cancer
Matti et al. European Journal of Hybrid Imaging (2017) 1:5 DOI 10.1186/s41824-017-0007-x European Journal of Hybrid Imaging SHORT COMMUNICATION Open Access Interpretation of 11C choline PET/CT for the
More informationROLE OF PET-CT IN BREAST CANCER, GUIDELINES AND BEYOND. Prof Jamshed B. Bomanji Institute of Nuclear Medicine UCL Hospitals London
ROLE OF PET-CT IN BREAST CANCER, GUIDELINES AND BEYOND Prof Jamshed B. Bomanji Institute of Nuclear Medicine UCL Hospitals London CANCER Key facts Estimated 15.2 million new cases per year in 2015 worldwide
More informationThe Use of PET Scanning in Urologic Oncology
The Use of PET Scanning in Urologic Oncology Dr Nicholas C. Buchan Uro-oncology Fellow 1 2 Aims To understand the basic concepts underlying PET scanning. Understand the emerging role of PET Scanning for
More informationDisease State Overview and Unmet Clinical Need
Disease State Overview and Unmet Clinical Need In 2016 an estimated 180,890 American men will be diagnosed with prostate cancer, making it the most commonly diagnosed non cutaneous neoplasm in men in the
More informationHormone therapy works best when combined with radiation for locally advanced prostate cancer
Hormone therapy works best when combined with radiation for locally advanced prostate cancer Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Introduction Introduction 1/3 of patients
More information